Q3 2020 Earnings

Revenue

$53M+3.2% YoY

Gross Profit

$33M62.0% margin

Operating Income

$3M5.3% margin

Net Income

$434,0000.8% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+9.3%

Operating Cash Flow

-$2M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Total Assets

$463M

Total Liabilities

$267M

Stockholders' Equity

$195M

Cash & Equivalents

$18M

Metric	Current	Year Ago	Change
Revenue	$53M	$51M	+3.2%
Gross Profit	$33M	$36M	-9.6%
Operating Income	$3M	$7M	-61.8%
Net Income	$434,000	$4M	-88.7%

Sales Of Generic Pharmaceutical Products

$38M64%

Sales Of Branded Pharmaceutical Products

$12M21%

Sales Of Contract Manufactured Products

$8M13%

Royalties From Licensing Agreements

$339,0001%

Product Development Services

$289,0000%

Other Revenues

$76,0000%

$52M98%

$885,0002%